Eli Lilly has chosen West Creek Business Park near Richmond, Virginia, to build a $5 billion manufacturing plant dedicated to producing active pharmaceutical ingredients (APIs) for monoclonal antibodies and antibody-drug conjugates (ADCs). This facility marks the first of four new U.S. manufacturing sites Lilly announced to expand domestic capacity. The investment underscores Lilly’s commitment to innovation, job creation, and strengthening resilient pharmaceutical supply chains in the United States.